2Butchart EG, Li HH, Payne N, et al. Twenty years'experience with the Medtronic Hall valve [ J]. J Thorac Cardiovasc Surg, 2001, 121: 1090- 1100.
3Aagaard J, Tingleff J, Hansen CN, et al. Twelve years' clinical experience with the CarboMedics prosthetic heart valve [ J ]. J Heart Valve Dis, 2001, 10: 177- 184.
4Salem DN, Stein PD, A1 - Ahmad A, et al. Antithrombotic therapy in valvular heart disease- - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [ J ]. Chest, 2004, 126: 457-482.
6Moil T, Asano M, Ohtake H, et al. Anticoagulant therapy after prosthetic valve replacement- optinml PT- INR in Japanese patients [J]. Ann Thorac Cardiovasc Surg, 2002, 8: 83-87.
8You JH, Chan FW, Wong RS, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate- intensity antieoagulation.9 [ J ] Br J Clin Phannaeol, 2005, 59 (5): 582-587.
9Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American Col- lege of Cardiology Foundation guide to warfarin therapy [ J ]. J Am Coil Cardiol, 2003, 41 (9) : 1633- 1652.
10David MW, Chang P, David LA, et al. Comparison of plasma prothrombin and factor Ⅶ and urine prothrombin F1 concentration in palients on longterm warfarin therapy and those in the initial phase [ J ]. Am Hematol, 1998, 57:193- 199.
6Acar J, lung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation, 1996,94:2107-2112.
7Uetsuka Y, Hosoda S, Kasanuki H, et al. Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single institution using conversion from thrombotest to FT-INR. Heart Vessels, 2000,15:124-128.
8Mori T, Asano M, Ohtake H, et al. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients.Ann Thorac Cardiovasc Surg, 2002,8:83-87.
9Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatment with warfarin in Chinese population. Ann Pharmacother, 2000,34:1395-1401.
10Hirsh J, Dalen JE, Deykin D, et al. Oral antlcoagulants:mechanism of action. Clinical effectiveness and optimal therapeutic range. Chest, 1992,102(Suppl) :S312-S326.
